Loading data for ENVB — first visit, this takes a few seconds.
Enveric Biosciences, Inc. (ENVB) Aktienkurs, Analyse & Daten
Innerer Wert
Analystenprognose
Aktienprognosen →Letzte Ergebnisse
| Gemeldet | Vs. Schätzung | YoY-Veränderung | |
|---|---|---|---|
| Umsatz | $0 | n/a | n/a |
| EPS | -$2,03 | +$0,73 | +98.94% |
Kennzahlen
- Geld
- 1.08
- Marktkapitalisierung
- 6.36M
- Umsatz (TTM)
- n/a
- Nettogewinn (TTM)
- -12.1M
- 1.11
- -12.18
- n/a
- -1.01
- KBV (TTM)
- 0.69
- KUV (TTM)
- n/a
- Termin Quartalszahlen
- n/a
- Brief
- 1.81
- Volumen
- 104,183
- Ø Vol. (20D)
- 120,341
- Eröffnung
- 1.48
- Vortagesschluss
- 1.44
- Tagesspanne
- 1.41 - 1.54
- 52-Wk Range
- 1.17 - 13.25
- Analyst
- n/a
- Kursziel
- n/a
- Dividenden
- n/a
- Ex-Dividenden-Datum
- Apr 23, 2008
Über Enveric Biosciences, Inc.
Profil ansehen →Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Branche Biotechnology
Sektor Healthcare
IPO Datum May 4, 2015
Mitarbeiter 5
Börse NasdaqCM
Tickersymbol ENVB
Website https://www.enveric.com